<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310232</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-076080</org_study_id>
    <secondary_id>HC File 9427-J0921-22C</secondary_id>
    <nct_id>NCT00310232</nct_id>
  </id_info>
  <brief_title>Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)</brief_title>
  <official_title>Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech Products, L.P.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of this study is to improve the Quality of Life (QoL) of selected
      patients with advanced carcinoma of the lung. The specific objective is to evaluate the
      effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related
      QoL and anemia in non-small cell lung cancer patients with advanced stage disease and
      underlying anemia of malignancy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recommendation of DSMB for safety issue, increased mortality with study drug.
  </why_stopped>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in anemia and fatigue related QoL at 12 weeks following randomization</measure>
    <time_frame>12 weeks following randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall QoL and domain-specific QoL scores</measure>
    <time_frame>16 weeks following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin and hematocrit levels</measure>
    <time_frame>6 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of transfusions</measure>
    <time_frame>6 months from randomization</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed non-small cell lung cancer (squamous cell, large cell,
             adenocarcinoma, or some combination of these), with clinical or pathological stage III
             or IV, or recurrent disease; and

          2. Hemoglobin level at or below 120 g/L; and

          3. At least 18 years of age;

        Exclusion Criteria:

          1. Systemic platinum-based chemotherapy for lung cancer during the previous two months or
             planned platinum-based chemotherapy within the next three months;

          2. Patients previously treated with high dose thoracic radiation (&gt;10 fractions), or
             surgery, without objective evidence of disease recurrence;

          3. Planned high dose thoracic radiation therapy (&gt;10 fractions);

          4. A clinically active malignancy, other than the underlying lung cancer which is
             expected to influence QoL;

          5. Expected survival of three months or less;

          6. ECOG Performance status of 3 or 4 (see Appendix D);

          7. Multiple CNS metastasis or a single CNS lesion that does not demonstrate radiographic
             stability (Screening CT of head required only if symptomatic, no radiographic
             follow-up of single resected lesions required);

          8. Blood transfusions within the last 14 days;

          9. Previous use of erythropoietin;

         10. Anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or
             gastrointestinal bleeding);

         11. Evidence of untreated folate or vitamin B12 deficiency;

         12. History of uncontrolled hypertension or diastolic blood pressure greater than 100 mm
             Hg;

         13. History of seizure disorder;

         14. Known hypersensitivity to mammalian cell-derived products, albumin or any component of
             the study drug;

         15. Pregnancy, lactation or parturition within the previous 30 days;

         16. Unwillingness or inability to complete the required QoL questionnaires;

         17. Mental incompetence, including psychiatric or addictive disorders which would preclude
             meaningful completion of questionnaires;

         18. Geographically inaccessible for treatment or follow-up evaluations;

         19. Currently enrolled in an ongoing therapeutic study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Wright, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamilton Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ontarion Clinical Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Regional Hospital</name>
      <address>
        <city>St. John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newfoundland Cancer Treatment &amp; Research Foundation</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Regional Cancer Centre (Juravinski)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>St. Catherines</city>
        <state>Ontario</state>
        <zip>L2K 5K3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeastern Ontario Regional Cancer Centre</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Clinical Trials Operations</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007 Mar 20;25(9):1027-32. Epub 2007 Feb 20.</citation>
    <PMID>17312332</PMID>
  </results_reference>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>June 29, 2007</last_update_submitted>
  <last_update_submitted_qc>June 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2007</last_update_posted>
  <keyword>Quality of Life</keyword>
  <keyword>Blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

